Jim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”

Group 1 - Summit Therapeutics Inc. (NASDAQ:SMMT) is currently facing negative sentiment due to issues related to its cancer screening drug, leading to cautious opinions from analysts [1][2] - The company is a biopharmaceutical firm focused on the discovery, development, and commercialization of therapies, with its lead candidate in Phase III trials for cancer treatment [2] - Analysts highlight that Summit Therapeutics has no revenues and has not made a profit, categorizing it as a speculative investment [2] Group 2 - Despite the potential of Summit Therapeutics, analysts suggest that certain AI stocks present greater upside potential and lower downside risk [2] - There is mention of insider buying in Summit Therapeutics, indicating some level of confidence from insiders, although overall sentiment remains negative [1]